Genocea Biosciences Inc (GNCAQ)

[NY1972]

I thought their P1 dose was too low. Clonal works in blood cancers with linear genetic drift, not solid cancers. Playing tug of war with cancer requires a division of 60/40 CD4/CD8.

Following the first disease evaluation by scan six-weeks post cNeT infusion, stable disease was observed in four out of the six patients and progressive disease in two. One patient had a reduction in the size of two of their four tumor lesions by approximately 55% and 90%. Engraftment data for our cNeTs are currently available from four patients, with evidence of engraftment in two. This tumor lesion reduction and the highest engraftment was in the patient who received the highest cell dose.